Trial of Aripiprazole in the Treatment of CD in Adolescents

Status Completed

Clinical Trial Summary

The proposed study will be a 6-week open label study evaluating aripiprazole in the treatment of 12 male post-pubertal adolescents (13-17 years, Tanner Stage 4) diagnosed with conduct disorder. The initial dose depending on the weight of the patient will be as follows: < 25 kg = 1 mg/d; 25-50 kg = 2 mg/d; 50-70 kg = 5 mg/d; > 70 kg = 10 mg/d (Data on File, 2003, Bristol-Myers Squibb). For the first two weeks of the study, the dose will be flexible based on response and tolerance and thereafter will remain fixed.

Clinical Trial Description

The use of atypical antipsychotics in children began in 1992 with several small case series with clozapine. Since that time, five other atypical agents, risperidone, olanzapine, quetiapine, ziprasidone and aripiprazole have been introduced into the US market. The newer atypical agents are not associated with agranulocytosis that has limited the usefulness of clozapine. Among the atypical antipsychotics, risperidone has remained the most extensively studied in children and adolescents, for a variety of problems, including Tourette's disorder, conduct disorder, schizophrenia, aggression, and pervasive development disorder. Risperidone has been shown to be an effective treatment in many of these disorders. However, weight gain, hyperprolactinemia, and extrapyramidal symptoms (EPS) are troublesome adverse effects more commonly associated with risperidone such that the drug's utility in this aged patient population is limited. We expect that the utility of aripiprazole in treating the pediatric population will not be limited by adverse effects like the other atypical antipsychotics. ;

Study Design

Related Conditions & MeSH terms

Conduct Disorder

Clinical Trial Details

NCT number	NCT00250705
Study type	Interventional
Source	University of Iowa
Contact
Status	Completed
Phase	Phase 4
Start date	November 17, 2004
Completion date	March 23, 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03535805` - Transdiagnostic, Cognitive and Behavioral Intervention for in School-aged Children With Emotional and Behavioral Disturbances	N/A
Recruiting	`NCT05449002` - Digital Single Session Intervention for Youth Mental Health	N/A
Withdrawn	`NCT02247986` - Investigating the Impact of Methylphenidate on Neural Response in Disruptive Behavioral Disorder	Phase 1/Phase 2
Recruiting	`NCT04631042` - Developing Brain, Impulsivity and Compulsivity
Completed	`NCT02485587` - Arousal-Biofeedback for the Treatment of Aggressive Behavior in Children and Adolescents	N/A
Completed	`NCT00819429` - Supplements and Social Skills Intervention Study	N/A
Completed	`NCT00626236` - Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems	Phase 2
Completed	`NCT01085305` - The Effectiveness of Parent-Child Interaction Therapy (PCIT)	N/A
Completed	`NCT00000385` - Long-Term Lithium Treatment for Aggressive Conduct Disorder	Phase 3
Completed	`NCT00250354` - A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation	Phase 3
Withdrawn	`NCT01443949` - Teenagers, Drug Addiction, and Reward and Impulse Control
Completed	`NCT04091633` - School Health Implementation Network: Eastern Mediterranean	N/A
Completed	`NCT02563145` - Real-time fMRI for the Treatment of Aggressive Behavior in Adolescents	N/A
Completed	`NCT02766101` - Manville Moves: an Exercise Intervention for Behavioral Regulation Among Children With Behavioral Health Challenges	N/A
Completed	`NCT00404911` - Multi-Family Group Therapy for Reducing Behavioral Difficulties in Youth	N/A
Completed	`NCT00051727` - Prevention of School Dropout for Mexican American Adolescents	Phase 2
Completed	`NCT02998073` - Investigating Psychosocial Intervention Treatment Response in Justice-Involved Youth With Conduct Disorder	N/A
Completed	`NCT03292848` - Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders	Phase 1
Recruiting	`NCT06373484` - Matching Assessment and Treatment for Children With Disruptive Behaviour and Their Parents	N/A
Recruiting	`NCT05637320` - Big Feelings: A Study on Children's Emotions in Therapy	N/A